Get the Stockscreener App
2.19
1.35%
-0.03
After Hours:
2.19
Black Diamond Therapeutics Inc stock is traded at $2.19, with a volume of 445.69K.
It is down -1.35% in the last 24 hours and down -17.05% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.22
Open:
$2.21
24h Volume:
445.69K
Relative Volume:
0.38
Market Cap:
$124.78M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.1649
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+1.39%
1M Performance:
-17.05%
6M Performance:
-13.78%
1Y Performance:
-3.10%
1-Day Range:
$2.13
$2.23
1-Week Range:
$2.13
$2.365
52-Week Range:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.19 | 126.48M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Macro Review: Is Black Diamond Therapeutics Inc a strong growth stockWeekly Trading Summary & Growth Focused Entry Reports - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (BDTX) price target trimmed as Piper updates biotech models and 2026 catalyst tracker - MSN
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker - Finviz
Dow Update: What is Black Diamond Therapeutics Incs revenue forecast2025 Biggest Moves & Daily Growth Stock Investment Tips - baoquankhu1.vn
What’s the profit margin of Black Diamond Therapeutics Inc.Take Profit & Safe Entry Zone Tips - mfd.ru
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer - BioSpace
How much upside does Black Diamond Therapeutics Inc. haveJuly 2025 Big Picture & Detailed Earnings Play Strategies - mfd.ru
Entry Recap: Can Black Diamond Therapeutics Inc maintain sales growthRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Reactions: Does Black Diamond Therapeutics Inc outperform in volatile markets2025 Key Highlights & Expert Approved Trade Ideas - baoquankhu1.vn
Growth Review: Is Black Diamond Therapeutics Inc stock good for income investorsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Is Black Diamond Therapeutics (BDTX) stock outpacing its medical peers this year? - MSN
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aug Patterns: Does Black Diamond Therapeutics Inc outperform in volatile marketsJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Market Review: Whats the profit margin of Black Diamond Therapeutics IncEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 39.9% in December - Defense World
Piper Sandler Maintains Rating but Lowers Price Target for BDTX | BDTX Stock News - GuruFocus
Declining Stock and Solid Fundamentals: Is The Market Wrong About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)? - Yahoo Finance
Growth Value: What is the long term forecast for MPLX LP Limited Partnership stockJuly 2025 Big Picture & Weekly Chart Analysis and Guides - baoquankhu1.vn
Is Research Solutions Inc stock technically oversoldJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Profit Recap: Is Black Diamond Therapeutics Inc forming a bullish divergenceMarket Sentiment Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Jobs Data: Why Black Diamond Therapeutics Inc stock could outperform in 2025Earnings Recap Report & Real-Time Volume Surge Alerts - Bộ Nội Vụ
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Zacks Research - Defense World
What margin trends mean for Black Diamond Therapeutics Inc. stockFootwear buying guidance for urban daily use on hard surfaces focuses on foot fatigue reduction, making it designed for long term daily comfort. - ulpravda.ru
Published on: 2026-01-11 01:14:22 - Улправда
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
What Makes Black Diamond (BDTX) a New Strong Buy Stock - sharewise.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Why Black Diamond Therapeutics Inc. stock could benefit from AI revolution2025 Sector Review & Real-Time Stock Price Movement Reports - Улправда
Is Black Diamond Therapeutics Inc. stock supported by innovation pipelineProduct Launch & AI Powered Buy/Sell Recommendations - Улправда
สล็อต - Early Times
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Black Diamond Therapeutics’ Silevertinib shows 60% response rate in preliminary phase 2 lung cancer data - MSN
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Insider Monkey
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
What analysts say about Black Diamond Therapeutics Inc stockCandlestick Trading Patterns & High Return Trading Ideas - earlytimes.in
Would You Still Hold Black Diamond Therapeutics Stock If It Fell Another 30%? - Trefis
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to NASDAQ Biotechnology Index - marketscreener.com
BDTX (Black Diamond Therapeutics) EV-to-OCF : 1.30 (As of Dec. 21, 2025) - GuruFocus
Can Black Diamond Therapeutics Inc. stock deliver strong Q4 earnings2025 Institutional Moves & Daily Market Momentum Tracking - DonanımHaber
Can Black Diamond Therapeutics Inc. stock withstand economic slowdown2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
What momentum indicators show for Black Diamond Therapeutics Inc. stockWeekly Stock Summary & Accurate Trade Setup Notifications - Улправда
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):